434 related articles for article (PubMed ID: 18715208)
21. [POERT2].
Racická E
Vnitr Lek; 2015 Jan; 61(1):8-9. PubMed ID: 25989629
[No Abstract] [Full Text] [Related]
22. Insulin detemir: a long-acting insulin product.
Jones MC; Patel M
Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
[TBL] [Abstract][Full Text] [Related]
23. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes.
Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K;
Diabetes Care; 2001 Nov; 24(11):2005-6. PubMed ID: 11679478
[No Abstract] [Full Text] [Related]
24. [Long-acting insulin analogs: progressing slowly].
Holleman F; Hoekstra JB
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
26. [Long acting insulin analogs: possibly more stable glucose regulation].
Huvers F
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1674-8. PubMed ID: 15453119
[TBL] [Abstract][Full Text] [Related]
27. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
Pscherer S; Dietrich ES; Dippel FW; Neilson AR
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
Valentine WJ; Palmer AJ; Erny-Albrecht KM; Ray JA; Cobden D; Foos V; Lurati FM; Roze S
Adv Ther; 2006; 23(2):191-207. PubMed ID: 16751153
[TBL] [Abstract][Full Text] [Related]
29. Re: trial comparing insulin detemir with insulin glargine.
Swinnen S; Holleman F
Clin Ther; 2009 May; 31(5):1124-5; author reply 1125-6. PubMed ID: 19539113
[No Abstract] [Full Text] [Related]
30. Insulin detemir in the treatment of type 1 and type 2 diabetes.
Philips JC; Scheen A
Vasc Health Risk Manag; 2006; 2(3):277-83. PubMed ID: 17326333
[TBL] [Abstract][Full Text] [Related]
31. Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes.
Jendle J; Ridderstråle M; Torfvitt O; Ericsson A; Larsen S
J Med Econ; 2012; 15(2):261-3. PubMed ID: 22142237
[TBL] [Abstract][Full Text] [Related]
32. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
Garg SK
Diabetes Technol Ther; 2010 Jan; 12(1):11-24. PubMed ID: 20082581
[TBL] [Abstract][Full Text] [Related]
33. Insulin combination therapy in type 2 diabetes mellitus.
Hassan Y; Gupta G; Hassan S
Ann Intern Med; 2004 Apr; 140(8):666; author reply 667. PubMed ID: 15096346
[No Abstract] [Full Text] [Related]
34. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
Valentine WJ; Jendle J; Saraheimo M; Thorsteinsson B; Pollock RF; Lammert M
Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
[TBL] [Abstract][Full Text] [Related]
35. Insulin combination therapy in type 2 diabetes mellitus.
Mikhail N; Wali S
Ann Intern Med; 2004 Apr; 140(8):666-7; author reply 667. PubMed ID: 15096347
[No Abstract] [Full Text] [Related]
36. Insulin Glargine: a review 8 years after its introduction.
Goykhman S; Drincic A; Desmangles JC; Rendell M
Expert Opin Pharmacother; 2009 Mar; 10(4):705-18. PubMed ID: 19284367
[TBL] [Abstract][Full Text] [Related]
37. [Insulin glargine--a systematic review of clinical studies. No documented advantages with Lantus compared to NPH insulin].
Björck Linné A; Liedholm H
Lakartidningen; 2004 Jul; 101(30-31):2402-7. PubMed ID: 15314935
[TBL] [Abstract][Full Text] [Related]
38. Hypoglycaemia, analogue insulins; prescribing cost or quality of life?
Hitman GA
Diabet Med; 2012 Mar; 29(3):289. PubMed ID: 22364579
[No Abstract] [Full Text] [Related]
39. The fallacy of hindsight: response to Moses and Koenen.
Holleman F; DeVries JH
Diabetes Technol Ther; 2010 Oct; 12(10):833-4. PubMed ID: 20809683
[No Abstract] [Full Text] [Related]
40. Newer basal insulin analogues: degludec, detemir, glargine.
Kalra S
J Pak Med Assoc; 2013 Nov; 63(11):1442-4. PubMed ID: 24392539
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
